DEXWireNews

DEXWireNews

United Continental Airlines yesterday was the Knight in shinning Armour for investors in NYSE:AVH as the battle commences to keep their planes in the air. They company is crippled with debt has a very limited fleet of old planes after leasing companies took repossession after repayments were defaulted upon. UCA will now loan the company money and build its own...

DEXWireNews

Revolution Lighting Technologies stated Friday that on May 22, 2019, the Company received a letter from the Nasdaq Hearings Panel of The Nasdaq Stock Market informing the Company that the Panel has granted the Company’s request to stay the suspension of the Company’s securities from Nasdaq pending a final determination from the Panel regarding the Company’s...

DEXWireNews

Heightened tension between China and the USA have had a massive impact on the stock of NYSE:NIO but that is not the only reason. The stock finds itself at a all time low after producing very poor earnings in the previous quarter and that is unlikely to change. Competition within the sector is also mounting as the displacement away from gas intensifies, which...

DEXWireNews

Difficult to build a case for this as it is purely speculation and rumor that has highlighted the stock of NASDAQ:CLVS . There has been some option activity which is encouraging and positive trial data which failed to rally the stock. The contrarian long option is going against strong negatives such as, high debt, decreasing pricing power, insider selling and...

DEXWireNews

It has become a real "I'm the biggest Bear" among the Analysts community to get a ridiculously low downgrade onto the CNBC Merry go round. Today may be the final day for the Bears to party, Gene Munster today was less than complementary regarding TSLA's future under Musk, he is a highly regarded analyst and his opinion counts. The fact he did not make a silly...

DEXWireNews

*********alert ******* NASDAQ:SANW STOCK HAS BEEN Halted this morning on unusual volume and news pending within conference call at 11.00 ET . Stock had gaped up 24% before been halted, strong watch for today ANALYSTS PRICE TARGET $4.83 ANALYSTS RECOMMENDATION BUY COMPANY PROFILE S&W Seed Co. is an agricultural company, which engages in the production and...

DEXWireNews

Shares of LB have rallied on Thursday morning as a result of the company announcing a surprise profit in the quarter and also raising guidance for the year to come. This could result in a massive rally in the days to come as the stock has lost 40% of value in 6 months and was actually down 5% yesterday prior to the earnings report. COMPANY PROFILE L Brands, Inc....

DEXWireNews

*****CONTINUATION LOOKS ON THE CARDS TODAY, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOD VOLUME . CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING. ***********NEWS FLOW********* The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that...

DEXWireNews

************************A CAVALCADE OF GOOD NEWS LATELY IN NASDAQ:NOVN HAS SPURNED A EPIC RALLY FROM LATE APRIL. NOT TO WORRY IF YOU HAVE NOT BEEN INVOLVED THERE IS PLENTY OF ACTION LEFT IN THIS NAME AS INSIDERS HAVE BEEN BUYING UP SHARES. A BREAK ABOVE $2.45 IS A GOOD BUY SIGNAL ON GOOD VOLUME ********************* On May 6, it announced that it sold the...

DEXWireNews

****** HUGE MOVE ON THE WAY TODAY, THIS COULD REALLY ROCKET HIGHER****************** Thinly traded micro cap Valeritas Holdings (NASDAQ:VLRX) is up 38% premarket on increased volume in reaction to new data from the VERDICT study, a real-world retrospective analysis of electronic medical records from a large diabetes center. Patients with HbA1c levels greater...

DEXWireNews

*****SPECULATION IS WE COULD GET A SIZEABLE MOVE IN THE STOCK TODAY WITH W EASY 30% GAIN********************* SET ALERTS FOR A POSSIBLE MOVE TO ABOVE $2 AVERAGE PRICE TARGET $9 AVERAGE RECOMMENDATION buy LEAP THERAPEUTICS INC. Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat...

DEXWireNews

*******STRONG BREAKOUT COMING**** Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug...

DEXWireNews

NASDAQ:USAT Shares of USA Technologies (NASDAQ: USAT) climbed 12% on Tuesday after hedge fund Hudson Executive Capital disclosed a 12% stake in the troubled networking and cashless transaction company, this is on the back of a terrible 2019 for the company. WE EXPECT SERIOUS CONTINUATION ABOVE $7 IT WILL RUN HARD. The stock price is at a a critical point- Sitting...

DEXWireNews

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oragenics Inc (OGEN) today and set a price target of $2. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.38. Selvaraju observed: “We believe the Phase 2 study could report top-line results in early 2020. If AG013 could significantly reduce the duration and lower the...

DEXWireNews

The month of MAY has been quite interesting for NASDAQ:TROV having released earnings that beat but revenue that missed, it followed this up by securing a capital raise with Lincoln Park Capital Funds, which adds additional working capital to move forward with it clinical development programs. Speculation and rumors are quite active in the social platforms...

DEXWireNews

The speculation regarding a possible buyout has gathered steam, but we are of the opinion that the $9 price is lower than what the company is actually worth. The stock has a very high short interest of 21% which has helped drive down the price from $16 a year earlier. Just 2 Hedge funds are in control of 30% of the shares with 1 of those funds Armatice, having...

DEXWireNews

*****WE KEEP ALERTS SET ON THIS NAME AND BUY ORDER IN PLACE, RUMOR HAS IT THERE IS A MOVE COMING SOON, WITH MASSIVE UPSIDE POTENTIAL****** James mc Carthy from MAxim recently maintained his buy rating and initiated a $3 price target citing. “Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the...

DEXWireNews

Agile Therapeutics has resubmitted its U.S. marketing application for contraceptive patch Twirla, this follows the company receiving a CRL in December 2017 citing the need for additional adhesion data. Keep this on the watch-list for today and they weeks to come. When this moves it will be fast and frantic. Analyst Rating Overweight. 3 Buy 2 Hold Agile...